Bristol-Myers Squibb CoBMY:NYQ

1.18 / 1.65%
Latest price in USDToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Jun 29 2016 17:02 BST.


As of last trade Bristol-Myers Squibb Co (BMY:NYQ) traded at 72.81, 3.08 % below its 52-week high of 75.12, set on Jun 06, 2016.

52-week range
Aug 24 2015
Jun 06 2016
Markit short selling activity
Day high73.04
Day low71.96
Previous close71.63
Average volume7.85m
Shares outstanding1.67bn
Free float1.67bn
P/E (TTM)75.43
Market cap117.87bn USD
EPS (TTM)0.9361 USD
Annual div (IAD)1.52 USD
Annual div yield (IAD)2.11%
Div ex-dateJun 29 2016
Div pay-dateAug 01 2016
Data delayed at least 15 minutes, as of Jun 29 2016 17:02 BST.

Comparative analysis

Past 90 days
1 week1 month6 months1 year5 years
Bristol-Myers Squibb Co+0.69 %+2.10 %+4.73 %+10.37 %+155.12 %
S&P 500 INDEX-2.37 %-3.00 %-1.32 %-1.05 %+55.73 %
USA/HEALTH CARE-1.12 %-1.95 %-5.36 %-7.44 %+49.43 %
USA/PHARMACEUTICALS-0.06 %+0.53 %-1.25 %-2.57 %+45.93 %
Data delayed at least 15 minutes, as of Jun 29 2016 17:02 BST.
© Thomson Reuters Click for restrictions.

All markets data located on is subject to the FT Terms & Conditions.

All content on is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.

Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.